Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides

被引:125
作者
Krieg, AM [1 ]
机构
[1] Dept Vet Affairs Med Ctr, Iowa City, IA 52246 USA
[2] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[3] CpG ImmunoPharmaceut, Wellesley, MA 02481 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 1999年 / 1489卷 / 01期
基金
美国国家卫生研究院;
关键词
lymphocyte activation; B cell; monocyte; natural killer cell; immunomodulator;
D O I
10.1016/S0167-4781(99)00147-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immune stimulation has been widely recognized as an undesirable side effect of certain antisense oligodeoxynucleotides (ODN) which can interfere with their therapeutic application, It is now clear that these dose-dependent immune stimulatory effects primarily result from the presence of an unmethylated CpG dinucleotide in particular base contexts ('CpG motif'). The sequence-specific immune activation is not just an experimental artifact, but is actually a highly evolved immune defense mechanism whose actual 'goal' is the detection of microbial nucleic acids. In contrast to vertebrate DNA, in which CpG dinucleotides are 'suppressed' and are highly methylated, microbial genomes do not generally feature CpG suppression or methylation [1]. Immune effector cells such as B cells, macrophages, dendritic cells, and natural killer cells appear to have evolved pattern recognition receptors (PRR) that by binding the microbe-restricted structure of CpG motifs, trigger protective immune responses. Although the specific immune activation appears to have a variety of potential therapeutic applications, it is generally undesirable in antisense ODN. Immune stimulation may be avoided in antisense oligos by the selection of CpG-free target sequences, by the use of ODN backbones that do not support immune stimulation, or by selective modifications of the cytosine in any CpG dinucleotides. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 76 条
[1]   ANTIVIRAL ACTIVITY OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE COMPLEMENTARY TO RNA OF THE HUMAN CYTOMEGALOVIRUS MAJOR IMMEDIATE-EARLY REGION [J].
AZAD, RF ;
DRIVER, VB ;
TANAKA, K ;
CROOKE, RM ;
ANDERSON, KP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1945-1954
[2]  
Ballas ZK, 1996, J IMMUNOL, V157, P1840
[3]  
BENDIGS S, 1998, IN PRESS EUR J IMMUN
[4]   DNA-BINDING TO HUMAN-LEUKOCYTES - EVIDENCE FOR A RECEPTOR-MEDIATED ASSOCIATION, INTERNALIZATION, AND DEGRADATION OF DNA [J].
BENNETT, RM ;
GABOR, GT ;
MERRITT, MM .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (06) :2182-2190
[5]   CPG ISLANDS AS GENE MARKERS IN THE VERTEBRATE NUCLEUS [J].
BIRD, AP .
TRENDS IN GENETICS, 1987, 3 (12) :342-347
[6]   Characterization and modulation of immune stimulation by modified oligonucleotides [J].
Boggs, RT ;
McGraw, K ;
Condon, T ;
Flournoy, S ;
Villiet, P ;
Bennett, CF ;
Monia, BP .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1997, 7 (05) :461-471
[7]   IMMUNE STIMULATION BY AN ANTISENSE OLIGOMER COMPLEMENTARY TO THE REV GENE OF HIV-1 [J].
BRANDA, RF ;
MOORE, AL ;
MATHEWS, L ;
MCCORMACK, JJ ;
ZON, G .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (10) :2037-2043
[8]   Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12 [J].
Chace, JH ;
Hooker, NA ;
Mildenstein, KL ;
Krieg, AM ;
Cowdery, JS .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 84 (02) :185-193
[9]   CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].
Chu, RS ;
Targoni, OS ;
Krieg, AM ;
Lehmann, PV ;
Harding, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631
[10]  
Cowdery J, 1996, J IMMUNOL, V156, P4570